Streetbeat News

Products Services

RKLB

Rocket Lab USA, Inc. (RKLB) announced the launch window for its 45th Electron mission, 'Owl Night Long,' scheduled to begin on March 10th. This mission, Rocket Lab's fourth for Synspective, will deploy the StriX-3 Earth-imaging satellite from New Zealand. Synspective, utilizing SAR technology for its satellite constellation, aims to expand its data services and enhance its analytics platform. This launch marks Rocket Lab's third Electron mission in 2024, continuing its exclusive partnership with Synspective.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:40 pm

CSGP

CoStar Group reported a 13% increase in revenue for 2023. Apartments.com achieved over $1B in annualized run rate revenue in January 2024, and Homes.com surpassed $1M in annualized daily net new sales bookings in February 2024.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:34 pm

JNJ

Johnson & Johnson announced that the FDA has approved its Supplemental Biologics License Application for TECVAYLI, a significant development in its pharmaceutical division. This approval could potentially enhance the company's product portfolio and strengthen its position in the biologics market.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:33 pm

RKLB

TRIN

Trinity Capital Inc. (TRIN) has committed $120 million in equipment financing to Rocket Lab USA, Inc. (RKLB), a leading space launch and satellite technology provider. This financing will support Rocket Lab's expansion plans, including additional manufacturing capacity and R&D, following a $515 million contract with the Space Development Agency. Trinity's CEO, Kyle Brown, emphasized the partnership's role in advancing space innovation, while Rocket Lab's CFO, Adam Spice, highlighted the financing's contribution to scaling their launch and space systems businesses.

Portfolio Pulse from Happy Mohamed

February 20, 2024 | 9:29 pm

MATX

Matson anticipates its 2024 volume to mirror the 2023 levels, indicating slight economic growth in Hawaii and a stable market share. This projection suggests a steady operational outlook for the company.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:13 pm

THAR

Tharimmune Inc (NASDAQ:THAR) completed its Phase 1 clinical trial for TH104, a transmucosal buccal film for chronic liver disease, showing safety and tolerability comparable to FDA-approved nalmefene. The trial's full data is expected in Q2 2024. Last quarter, Tharimmune closed an $11 million public offering to extend its cash runway into early 2025 for TH104's clinical readouts. THAR shares rose 0.26% to $0.39.

Portfolio Pulse from Vandana Singh

February 20, 2024 | 9:10 pm

MOTS

Motus GI Holdings Inc. has been granted a U.S. patent (#11904085) for its innovative 'Systems and Methods for Cleaning a Colon'. This patent solidifies the company's intellectual property rights around its colon cleaning technology, potentially enhancing its competitive position in the medical device market.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 8:58 pm

AFIB

Acutus Medical has received a European patent (EP3294399) for a catheter system designed for left heart access, marking a significant milestone in the company's innovation trajectory.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 8:56 pm

SONY

Helldivers 2, funded by Sony Group Corp. (NYSE:SONY), reached 409,337 concurrent players on Steam, making it the fifth most popular game despite its $40 price tag. The game, released on Feb. 8, faced server issues due to high demand but saw improvements. CEO Johan Pilestedt advised players to wait until server capacity improves for a better experience. The game's success is notable, especially with its higher price compared to the top paid title, Palworld.

Portfolio Pulse from Franca Quarneti

February 20, 2024 | 8:50 pm

CANE

The Teucrium Sugar Fund ETF (NYSE:CANE) is experiencing a downtrend since Feb. 12, amidst expectations of a 20% increase in raw sugar prices by 2024 due to a global supply glut influenced by stable production in Brazil and stagnant growth in India. Despite the downtrend, CANE offers a unique investment opportunity as it tracks sugar futures, a commodity not moving in tandem with U.S. stock market trends, potentially serving as a market hedge. The ETF showed signs of a potential reversal with a dragonfly doji candlestick indicating a possible local bottom.

Portfolio Pulse from Melanie Schaffer

February 20, 2024 | 8:42 pm